Design Therapeutics Inc
DSGN
Market Cap$263.97M
Close$
$0.36
89.8% downside
Current Fair Value
89.8% downsideOvervalued by 89.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $263.97 Million |
|---|---|
| Enterprise Value | $243.75 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.88 |
| Beta | 1.82 |
| Outstanding Shares | 56,587,142 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -5.31 |
|---|---|
| PEG | 30.47 |
| Price to Sales | - |
| Price to Book Ratio | 0.88 |
| Enterprise Value to Revenue | 290.87 |
| Enterprise Value to EBIT | -4.01 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Design Therapeutics Inc
15 employeesDesign Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on the treatment of Friedreich ataxia, foll...